Treatment for Hemophilia A
Wilate is a medication derived from human plasma, used to control bleeding in adolescents and adults with hemophilia A. It is manufactured to the highest standards for safety and efficacy.
Balanced 1:1 Formulation of VWF/FVIII1-3
- The wilate 1:1 ratio is similar to the ratio of VWF to FVIII that is found naturally in the body
High-Purity VWF/FVIII Complex
- wilate is purified through a series of carefully controlled processing steps, all designed to minimize impurities and help reduce the risk of side effects.
- wilate is made from large pools of human plasma, collected in Octapharma plasma centers that are licensed by the US Food and Drug Administration (FDA).
- All plasma undergoes extensive testing for evidence of a wide range of viruses, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Any plasma that has evidence of these viruses is rejected.
Size exclusion chromatography
One of the steps in the wilate purification process is called size exclusion chromatography. This step minimizes impurities and helps reduce the risk of side effects.1,3,4 When the results of the advanced size exclusion chromatography are analyzed, wilate shows a single peak (see figure) containing only the native (natural) VWF/FVIII complex.3,4
- No albumin is added to wilate
Added plasma proteins may cause clinical side effects
Double Virus Inactivation Processes
Additional steps in the purification process help ensure that wilate is a safe, high-purity treatment for hemophilia A.
- A proven and established method used widely in the purification of products made from human plasma
- Inactivates viruses by breaking down the outer layer that surrounds them (sometimes called “an enveloped virus”)
- Effective against enveloped viruses, such as HIV, HBV, HCV and West Nile Virus
- Developed to supplement the S/D process
- Uses dry heat (100°C, for 2 hours) to inactivate viruses
- Effective against a broad spectrum of both enveloped and non-enveloped viruses
- wilate Full Prescribing Information. Hoboken, NJ: Octapharma; rev September 2019.
- Stadler M, et al. Biologicals. 2006;34:281-288.
- Berntorp E, et al. Haemophilia. 2009;15:122-130.
- Data on file, Octapharma USA; 2011.
- Farrugia A. Guide for the assessment of clotting factor concentrates. World Federation of Hemophilia. Last updated 2008.